Compare Stocks: LQDA, ZTS, VTRS, and JAZZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAZZ Jazz Pharmaceuticals	$244.96 -0.4%	$242.80	$116.53 ▼ $265.05	$15.90B	0.32	815,200 shs	542,030 shs
LQDA Liquidia	$74.44 +3.2%	$78.67	$21.15 ▼ $93.61	$6.66B	0.58	1.63 million shs	2.52 million shs
VTRS Viatris	$16.23 +1.2%	$16.58	$9.43 ▼ $18.39	$18.64B	0.9	11.27 million shs	8.20 million shs
ZTS Zoetis	$73.64 -2.9%	$76.30	$71.45 ▼ $160.48	$30.49B	0.74	7.04 million shs	4.45 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAZZ Jazz Pharmaceuticals	0.00%	-4.52%	+1.15%	+7.08%	+109.15%
LQDA Liquidia	0.00%	-17.49%	-1.10%	+30.76%	+195.40%
VTRS Viatris	0.00%	-1.22%	-6.35%	-1.52%	+55.91%
ZTS Zoetis	0.00%	+1.53%	-4.38%	-0.63%	-51.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAZZ Jazz Pharmaceuticals	$244.96 -0.4%	$242.80	$116.53 ▼ $265.05	$15.90B	0.32	815,200 shs	542,030 shs
LQDA Liquidia	$74.44 +3.2%	$78.67	$21.15 ▼ $93.61	$6.66B	0.58	1.63 million shs	2.52 million shs
VTRS Viatris	$16.23 +1.2%	$16.58	$9.43 ▼ $18.39	$18.64B	0.9	11.27 million shs	8.20 million shs
ZTS Zoetis	$73.64 -2.9%	$76.30	$71.45 ▼ $160.48	$30.49B	0.74	7.04 million shs	4.45 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAZZ Jazz Pharmaceuticals	0.00%	-4.52%	+1.15%	+7.08%	+109.15%
LQDA Liquidia	0.00%	-17.49%	-1.10%	+30.76%	+195.40%
VTRS Viatris	0.00%	-1.22%	-6.35%	-1.52%	+55.91%
ZTS Zoetis	0.00%	+1.53%	-4.38%	-0.63%	-51.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JAZZ Jazz Pharmaceuticals	3.00	Buy	$272.89	11.40% Upside
LQDA Liquidia	2.45	Hold	$98.08	31.76% Upside
VTRS Viatris	2.57	Moderate Buy	$17.50	7.83% Upside
ZTS Zoetis	2.32	Hold	$109.62	48.85% Upside

Current Analyst Ratings Breakdown

Latest LQDA, ZTS, VTRS, and JAZZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	LQDA Liquidia	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$79.00 ➝ $92.00
8/12/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$109.00 ➝ $111.00
8/12/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $110.00
8/12/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Hold	$90.00
8/11/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$280.00 ➝ $283.00
8/11/2026	ZTS Zoetis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$112.00 ➝ $96.00
8/11/2026	ZTS Zoetis	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$146.00 ➝ $110.00
8/10/2026	ZTS Zoetis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JAZZ Jazz Pharmaceuticals	$4.60B	3.46	$16.27 per share	15.06	$73.97 per share	3.31
LQDA Liquidia	$158.32M	42.09	N/A	N/A	$2.18 per share	34.15
VTRS Viatris	$14.30B	1.30	$7.38 per share	2.20	$12.42 per share	1.31
ZTS Zoetis	$9.47B	3.21	$7.55 per share	9.75	$7.62 per share	9.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	16.89	10.99	0.22	20.45%	33.97%	13.02%	11/4/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	54.34	17.00	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
VTRS Viatris	-$3.51B	-$0.36	N/A	6.10	1.46	-2.79%	20.02%	8.02%	N/A
ZTS Zoetis	$2.67B	$6.07	12.13	11.11	1.28	27.49%	74.89%	18.59%	11/3/2026 (Estimated)

Latest LQDA, ZTS, VTRS, and JAZZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	VTRS Viatris	$0.6010	$0.69	+$0.0890	-$0.10	$3.68 billion	$3.76 billion
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	$1.87	+$0.02	$1.65	$2.50 billion	$2.47 billion
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
VTRS Viatris	$0.48	2.96%	N/A	N/A	N/A
ZTS Zoetis	$2.12	2.88%	+20.11%	34.93%	14 Years

Latest LQDA, ZTS, VTRS, and JAZZ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/3/2026	VTRS Viatris	quarterly	$0.12	2.71%	8/21/2026	8/21/2026	9/16/2026
5/20/2026	ZTS Zoetis	quarterly	$0.53	2.78%	7/20/2026	7/20/2026	9/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
LQDA Liquidia	0.63	2.31	2.03
VTRS Viatris	0.81	1.58	0.96
ZTS Zoetis	2.87	3.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JAZZ Jazz Pharmaceuticals	89.14%
LQDA Liquidia	64.54%
VTRS Viatris	79.88%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
JAZZ Jazz Pharmaceuticals	4.10%
LQDA Liquidia	25.60%
VTRS Viatris	0.28%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable
VTRS Viatris	30,000	1.15 billion	1.15 billion	Optionable
ZTS Zoetis	14,500	413.22 million	412.32 million	Optionable

LQDA, ZTS, VTRS, and JAZZ Headlines

Recent News About These Companies

Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap

August 16 at 8:51 AM | seekingalpha.com

Russell Investments Group Ltd. Has $64.44 Million Stock Holdings in Zoetis Inc. $ZTS

August 16 at 6:47 AM | marketbeat.com

Mitsubishi UFJ Trust & Banking Corp Sells 14,700 Shares of Zoetis Inc. $ZTS

August 16 at 6:31 AM | marketbeat.com

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Lowers Stock Position in Zoetis Inc. $ZTS

August 16 at 6:31 AM | marketbeat.com

Zoetis Inc. $ZTS Stock Holdings Increased by Moran Wealth Management LLC

August 16 at 6:23 AM | marketbeat.com

SFE Investment Counsel Has $332,000 Holdings in Zoetis Inc. $ZTS

August 16 at 6:23 AM | marketbeat.com

KBC Group NV Acquires 16,375 Shares of Zoetis Inc. $ZTS

August 16 at 6:16 AM | marketbeat.com

Janney Montgomery Scott LLC Sells 93,748 Shares of Zoetis Inc. $ZTS

August 16 at 6:15 AM | marketbeat.com

Capital Analysts LLC Trims Stock Position in Zoetis Inc. $ZTS

August 16 at 4:23 AM | marketbeat.com

HighTower Advisors LLC Has $18.21 Million Stock Holdings in Zoetis Inc. $ZTS

August 16 at 4:23 AM | marketbeat.com

Fifth Third Bancorp Decreases Stake in Zoetis Inc. $ZTS

August 16 at 4:07 AM | marketbeat.com

BLB&B Advisors LLC Sells 70,744 Shares of Zoetis Inc. $ZTS

August 16 at 3:27 AM | marketbeat.com

Zoetis Stock (ZTS) Opinions on Michael Burry's Investment

August 15 at 10:10 AM | quiverquant.comQ

Principal Financial Group Inc. Trims Stake in Zoetis Inc. $ZTS

August 15 at 7:11 AM | marketbeat.com

TD Asset Management Inc Sells 43,689 Shares of Zoetis Inc. $ZTS

August 15 at 7:11 AM | marketbeat.com

30,208 Shares in Zoetis Inc. $ZTS Purchased by Qsemble Capital Management LP

August 15 at 7:03 AM | marketbeat.com

Willis Investment Counsel Buys 31,787 Shares of Zoetis Inc. $ZTS

August 15 at 7:03 AM | marketbeat.com

Oppenheimer Asset Management Inc. Reduces Stock Holdings in Zoetis Inc. $ZTS

August 15 at 6:47 AM | marketbeat.com

Massachusetts Financial Services Co. MA Trims Stock Holdings in Zoetis Inc. $ZTS

August 15 at 6:23 AM | marketbeat.com

Hohimer Wealth Management LLC Buys Shares of 55,824 Zoetis Inc. $ZTS

August 15 at 6:23 AM | marketbeat.com

Zoetis, EPAM, Dropbox, Trade Desk, Samsara Trending

August 15 at 5:10 AM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, ZTS, VTRS, and JAZZ Company Descriptions

Jazz Pharmaceuticals NASDAQ:JAZZ

$244.96 -0.89 (-0.36%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$245.24 +0.28 (+0.12%)

As of 08/14/2026 07:56 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Liquidia NASDAQ:LQDA

$74.44 +2.34 (+3.25%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.33 +1.89 (+2.53%)

As of 08/14/2026 07:55 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Viatris NASDAQ:VTRS

$16.23 +0.19 (+1.18%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$16.18 -0.05 (-0.28%)

As of 08/14/2026 07:34 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Zoetis NYSE:ZTS

$73.64 -2.20 (-2.90%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$74.03 +0.39 (+0.52%)

As of 08/14/2026 07:59 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LQDA, ZTS, VTRS, and JAZZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LQDA, ZTS, VTRS, and JAZZ Earnings

Compare Dividends

Latest LQDA, ZTS, VTRS, and JAZZ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LQDA, ZTS, VTRS, and JAZZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, ZTS, VTRS, and JAZZ Company Descriptions

Jazz Pharmaceuticals NASDAQ:JAZZ

Liquidia NASDAQ:LQDA

Viatris NASDAQ:VTRS

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LQDA, ZTS, VTRS, and JAZZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LQDA, ZTS, VTRS, and JAZZ Earnings

Compare Dividends

Latest LQDA, ZTS, VTRS, and JAZZ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LQDA, ZTS, VTRS, and JAZZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, ZTS, VTRS, and JAZZ Company Descriptions

Jazz Pharmaceuticals NASDAQ:JAZZ

Liquidia NASDAQ:LQDA

Viatris NASDAQ:VTRS

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools